These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20664958)

  • 1. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats.
    Noguchi R; Yoshiji H; Ikenaka Y; Kaji K; Shirai Y; Aihara Y; Yamazaki M; Namisaki T; Kitade M; Yoshii J; Yanase K; Kawaratani H; Tsujimoto T; Fukui H
    Int J Mol Med; 2010 Sep; 26(3):407-13. PubMed ID: 20664958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Shirai Y; Aihara Y; Namisaki T; Yoshii J; Yanase K; Tsujimoto T; Kawaratani H; Fukui H
    Am J Physiol Gastrointest Liver Physiol; 2011 Jun; 300(6):G1094-104. PubMed ID: 21372165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats.
    Kitade M; Yoshiji H; Kojima H; Ikenaka Y; Noguchi R; Kaji K; Yoshii J; Yanase K; Namisaki T; Asada K; Yamazaki M; Tsujimoto T; Akahane T; Uemura M; Fukui H
    Hepatology; 2006 Oct; 44(4):983-91. PubMed ID: 17006938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis.
    Shirai Y; Yoshiji H; Noguchi R; Kaji K; Aihara Y; Douhara A; Moriya K; Namisaki T; Kawaratani H; Fukui H
    J Gastroenterol Hepatol; 2013 Apr; 28(4):723-30. PubMed ID: 23301938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of insulin resistance on the progression of chronic liver diseases.
    Kaji K; Yoshiji H; Kitade M; Ikenaka Y; Noguchi R; Yoshii J; Yanase K; Namisaki T; Yamazaki M; Moriya K; Tsujimoto T; Kawaratani H; Akahane T; Uemura M; Fukui H
    Int J Mol Med; 2008 Dec; 22(6):801-8. PubMed ID: 19020779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis.
    Noguchi R; Yoshiji H; Ikenaka Y; Kaji K; Aihara Y; Shirai Y; Namisaki T; Kitade M; Douhara A; Moriya K; Fukui H
    Hepatol Res; 2013 Jul; 43(7):765-74. PubMed ID: 23163573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model.
    Aihara Y; Yoshiji H; Noguchi R; Kaji K; Namisaki T; Shirai Y; Douhara A; Moriya K; Kawaratani H; Fukui H
    Hepatol Res; 2013 Nov; 43(11):1241-50. PubMed ID: 23448275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet.
    Kawaguchi K; Sakaida I; Tsuchiya M; Omori K; Takami T; Okita K
    Biochem Biophys Res Commun; 2004 Feb; 315(1):187-95. PubMed ID: 15013444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
    Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
    Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Anticancer Res; 2005; 25(5):3335-40. PubMed ID: 16101147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
    Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of renin-angiotensin system in antifibrotic therapy.
    Yoshiji H; Kuriyama S; Fukui H
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S93-5. PubMed ID: 17567477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic steatohepatitis and preneoplastic lesions develop in the liver of obese and hypertensive rats: suppressing effects of EGCG on the development of liver lesions.
    Kochi T; Shimizu M; Terakura D; Baba A; Ohno T; Kubota M; Shirakami Y; Tsurumi H; Tanaka T; Moriwaki H
    Cancer Lett; 2014 Jan; 342(1):60-9. PubMed ID: 23981577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Yamazaki M; Tsujinoue H; Imazu H; Fukui H
    Oncol Rep; 2003; 10(4):957-62. PubMed ID: 12792752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
    Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
    Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis.
    Beraza N; Malato Y; Vander Borght S; Liedtke C; Wasmuth HE; Dreano M; de Vos R; Roskams T; Trautwein C
    Gut; 2008 May; 57(5):655-63. PubMed ID: 18408102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of adipocytokines in hepatic fibrogenesis.
    Ikejima K; Okumura K; Kon K; Takei Y; Sato N
    J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S87-92. PubMed ID: 17567476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiogenesis in chronic liver disease and its complications.
    Coulon S; Heindryckx F; Geerts A; Van Steenkiste C; Colle I; Van Vlierberghe H
    Liver Int; 2011 Feb; 31(2):146-62. PubMed ID: 21073649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.
    Yoshiji H; Noguchi R; Kuriyama S; Ikenaka Y; Yoshii J; Yanase K; Namisaki T; Kitade M; Masaki T; Fukui H
    Am J Physiol Gastrointest Liver Physiol; 2005 May; 288(5):G907-13. PubMed ID: 15618280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
    Yoshiji H; Kuriyama S; Noguchi R; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Masaki T; Fukui H
    J Hepatol; 2005 May; 42(5):687-93. PubMed ID: 15826718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.